- Diabetes
- Endocrinology
- Regenerative Medicine
- +۶ مورد دیگر
Lorenzo Piemonti serves as Associate Professor of Endocrinology at Vita Salute San Raffaele University in Milan, Italy, and holds key leadership positions at the San Raffaele Scientific Institute where he directs the Diabetes Research Institute and the Department of Regenerative Medicine and Transplantation. He previously served as Visiting Professor at Vrije Universiteit Brussels (2016-2022) and will serve as President of the International Pancreas and Islet Transplantation Association (IPITA) for 2025-2027. His research focuses on diabetes pathophysiology, beta cell biology, and regenerative medicine approaches to diabetes treatment. Key areas include beta cell replacement therapies, immune tolerance induction strategies, stem cell differentiation for insulin-producing cells, and the development of biomaterials to support islet transplantation. He has pioneered work in dendritic cell biology related to diabetes autoimmunity and has significant contributions to pancreatic oncology research. Dr. Piemonti's recent publications demonstrate a strong focus on translational research bridging basic science discoveries with clinical applications, particularly in islet transplantation outcomes, stem cell-derived beta cells, immune tolerance strategies, and precision medicine approaches to diabetes classification and treatment. Premio Alcmeone (2012) from Società Italiana di Diabetologia Premio per Giovani Ricercatori (2005) from Fondazione Guido Berlucchi As a physician-scientist, Dr. Piemonti maintains active editorial roles as Section Editor for Cell Transplantation and Associate Editor for Transplant International and Journal of Endocrinological Investigation. His leadership extends to multiple international committees including the European Pancreas and Islet Transplant Registry steering committee and various roles within IPITA. He coordinates the European Consortium for Islet Transplantation, which has provided human beta cell products for research and clinical applications across Europe since 2000. His laboratory maintains active collaborations across multiple European institutions through the European Consortium for Islet Transplantation and participates in numerous clinical trials related to beta cell replacement therapies and immune interventions for diabetes.



